Revenue ($USD) : $1,120,800,000
R&D spend : $85,200,000
Employees : 2,200
Fiscal year end : 9/30/2023
CEO : Dev Kurdikar

www.embecta.com

BD diabetes spinoff Embecta submitted an open-loop, proprietary, disposable insulin patch pump for people with type 2 diabetes for FDA review in January 2024. It also has a closed-loop, automated version under development set to follow. In the meantime, Embecta looks like a potential acquisition target, as reports surfaced that the company enlisted advisers to look into a possible sale. –SW